2011年 · 第46卷第05期

intrahepatic cholestasis of pregnancy (ICP) is a disease that occurs in the middle and third trimester of pregnancy, and its etiology and pathogenesis are unknown so far. The disease is clinically characterized by skin pruritus, biochemically abnormal hematological indexes of intrahepatic cholestasis, and the course of the disease is characterized by clinical manifestations and biochemical abnormalities that rapidly disappear or return to normal after delivery. The incidence rate ranged from 0.8% to 12.0%, with obvious ethnic and regional differences. ICP is a benign disease for pregnant women, but it has serious adverse effects on perinatal infants, which can lead to premature delivery, contamination of amniotic fluid and meconium, unpredictable fetal death in utero, neonatal asphyxia, etc., increase the perinatal morbidity and mortality rate, and lead to the increase of cesarean section rate. Therefore, it is necessary to standardize the diagnosis and treatment of ICP.

intrahepatic cholestasis of pregnancy (ICP) is a serious complication of pregnancy and one of the main causes of increased perinatal mortality. There are obvious regional and ethnic differences in its occurrence. At present, there is no definite epidemiological data of ICP in China. So far, there is no consensus opinion on the diagnosis and treatment of ICP in the world, and there is also a lack of diagnosis and treatment guidelines based on evidence-based medicine and suitable for China. Therefore, the Obstetrics Group of Obstetrics and Gynecology Branch of Chinese Medical Association organized relevant domestic experts to formulate the "Guidelines for Diagnosis and Treatment of Intrahepatic Cholestasis in Pregnancy (1st Edition)". The purpose of this guideline is to help clinicians make reasonable clinical decisions on the diagnosis and treatment of ICP. It is not a mandatory standard, and it is impossible to include or solve all problems in the diagnosis and treatment of ICP. Therefore, when targeting a specific patient, clinicians should refer to this guideline. Based on the guideline, it is necessary to comprehensively evaluate the patient's specific condition and examination results, and formulate a reasonable diagnosis and treatment plan. This guideline will be continuously updated and refined as new research findings and evidence-based medicine on ICP become available.